US EditionPublished • loading... • Updated
Ocugen (NASDAQ: OCGN) Reports Strong Midstage Data for Gene Therapy
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Ocugen (NASDAQ: OCGN) Reports Strong Midstage Data for Gene Therapy
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) said preliminary 12-month data from its Phase 2 ArMaDa clinical trial showed meaningful reductions in disease progression for patients with geographic atrophy, a late-stage form of dry age-related macular degeneration, reinforcing the company’s push toward late-stage development of its investigational gene therapy, OCU410. The Phase 2 analysis, based on approximately half of enrolled patients evaluated t…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
